2486 results about "Endocrinology" patented technology

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The present disclosure provides methods of treating a neurodevelopmental disorder (NDD) in a subject by administering a therapeutically effective amount of N-acetyl leucine.

Disclosed are RAS(ON) multi-selective inhibitor compositions and methods of treating RAS protein-related diseases or disorders using an intermittent dosing regimen. RAS(ON) multi-selective inhibitors having tight binding to cyclophilin A (CypA) result in high exposure levels, prolonged tissue retention, and / or slow clearance rates, thereby increasing the risk of inhibition of wild-type RAS in normal tissues. Accordingly, provided herein are methods for the safe and effective dosing of low KD1 RAS(ON) multi-selective inhibitors using an intermittent dosing regimen. Also provided are methods of selecting or identifying such RAS(ON) multi-selective inhibitors suitable for intermittent administration.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

Disclosed herein are methods and compositions for preventing or reducing adverse events associated with administration of a RAS(ON) inhibitors. Thus, disclosed are compositions and methods for treating or preventing RAS(ON) inhibitor therapy-associated rash or mucositis. The methods involve administering a compound that binds to cyclophilin A (CypA) to compete with a RAS(ON) inhibitor for CypA binding, thereby reducing tri-complex formation in non-tumor tissues. These approaches may improve the tolerability of RAS(ON) inhibitor therapies without compromising efficacy.

The invention relates to the technical field of blood glucose prediction, in particular to a blood glucose fluctuation prediction method based on historical data. The method comprises the following steps: acquiring corresponding historical blood glucose monitoring data, daily behavior data, physiological status data and medical intervention data of a user, performing time axis alignment and abnormal value cleaning treatment, and extracting basic features and associated influence features corresponding to blood glucose fluctuation; performing space-time dimension fusion on the basic features and the associated influence features, and generating a blood glucose fluctuation prediction curve of the user in a future preset time period; performing comparative analysis on the blood glucose fluctuation prediction curve and actual blood glucose monitoring data of the user, calculating a prediction deviation degree and a trend goodness of fit, and generating a corresponding deviation analysis result; feature weight distribution of the dynamic prediction model is optimized based on the deviation analysis result, and a personalized blood glucose fluctuation prediction report is generated and comprises a risk early warning threshold value and an intervention suggestion triggering condition. According to the method, prediction efficiency and personalized management of blood glucose fluctuation can be realized.

The invention discloses a system and a method for intelligently monitoring blood sugar of a patient before and after diet based on food components, and belongs to the technical field of blood sugar monitoring, and the system comprises a food component quantification module which is used for converting a food image or description into accurate macro nutrient and micronutrient data; the multi-modal data fusion module is used for preprocessing and fusing the multi-modal data of the patient; the patient blood sugar prediction module is used for constructing a patient blood sugar prediction model to analyze the multi-modal fusion data of the patient and predicting the blood sugar of the patient; and the difference analysis optimization module is used for comparing actual blood glucose with predicted blood glucose after meal and analyzing difference reasons. The problems that blood glucose of a patient before and after eating cannot be intelligently monitored, and accurate quantification and prediction of the relation between diet and blood glucose cannot be achieved are solved. The system can intelligently monitor the blood glucose of the patient before and after eating, can help the diabetic to realize accurate quantification and prediction of the relationship between diet and blood glucose, and can effectively control the blood glucose and reduce the risk of complications.

The present disclosure relates to compositions and methods of increasing levels of fetal hemoglobin (HbF) in cells. The present disclosure further relates to methods for treating patients suffering from blood cell diseases, including those associated with reduced amounts of functional adult hemoglobin (HbA), such as sickle cell disease and β-thalassemias

The invention belongs to the technical field of animal breeding, and particularly relates to application of a detection reagent of an SNP (Single Nucleotide Polymorphism) molecular marker related to pork tenderness. An SNP site exists at the 232bp position from the 5'end of the sequence, the polymorphism is G / A, three genotypes of GG, GA and AA are shown, G allele is dominant allele, and the meat tenderness of a GG type individual is obviously higher than that of an AA type individual. The invention further develops a reagent for detecting the SNP molecular marker, the reagent can be used for pig assisted breeding, pig breeding or pork tenderness identification, and a method for identifying the pork tenderness is developed, which is beneficial to accelerating genetic breeding and early-stage seed selection of boars with high-quality meat traits.

This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.

The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.

Methods of insulin delivery may include selecting a basal insulin delivery rate responsive to a projected blood glucose level that approximates a target blood glucose level. Methods of insulin delivery may further include generating insulin delivery instructions for an insulin delivery device, the insulin delivery instructions corresponding to the basal insulin delivery rate and for a variable time duration relative to an intended time duration.

The present invention has an object of providing a composition that is effective for the treatment of a prototheca disease. According to the present invention, a composition containing ravuconazole as an active ingredient, which is administered to an animal suffering from a prototheca disease caused by Prototheca wickerhamii or Prototheca zopfii, is provided.

Described herein are pharmaceutical formulations of a farnesoid X receptor agonist, 4-((4-(1-(tert-butyl)-1H-pyrazol-4-yl)pyridin-2-yl)((4-(4-methoxy-3-methylphenyl)bicyclo[2.2.2]octan-1-yl)methyl)carbamoyl)cyclohexyl 3-hydroxyazetidine-trans-1-carboxylate, and methods of using such pharmaceutical formulations in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

The disclosure relates to compositions comprising a phentermine and a unicyclic aminoketone and methods of use thereof. The methods of use include inducing weight loss or reducing weight gain in a human subject. The unicyclic aminoketone may be diethylpropion or bupropion. In some embodiments, the compositions further include tadalafil or naltrexone.

The invention belongs to the field of food processing, and provides a preparation method of penaeus vannamei powder gel suitable for people with dysphagia, which comprises the following steps: taking penaeus vannamei meat, blending until no obvious particles exist, freezing, carrying out vacuum drying, powdering, sieving, mixing with water, fully hydrating to obtain a penaeus vannamei powder solution, adjusting the pH value of the penaeus vannamei powder solution to 9-11, stirring, adjusting the pH value to 6-8, and preparing the penaeus vannamei powder gel. And continuously stirring, adding carrageenan, heating and cooling to obtain the penaeus vannamei meal gel. The method disclosed by the invention is simple and easy to implement, and the pH migration treatment and the carrageenan treatment are utilized to generate a synergistic effect, so that the prepared penaeus vannamei powder gel meets the fifth-level standard of an IDDSI framework, and can meet the diet requirements of special crowds such as dysphagia patients on multiple aspects such as nutrition and texture.

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, cannabidiol-C6 (CBD-C6), is a naturally occurring cannabinoid that can be found in minor quantities in the cannabis plant. Furthermore, the cannabinoid can be produced by synthetic means and a method for the production of CBD-C6 is described herein. In addition, disclosed herein are data which demonstrate the efficacy of CBD-C6 in models of disease.

The invention relates to the technical field of functional food, in particular to immune regulation type prebiotic syrup with synergy of galactomannan. The active components of the composite solid beverage are prepared from the following raw materials in percentage by weight: 20%-35% of fructo-oligosaccharide, 10%-18% of galactooligosaccharide, 8%-15% of stachyose, 3%-7% of xylooligosaccharide, 5%-12% of lactitol, 5%-10% of galactomannan, 2%-5% of yeast beta-glucan and 1%-3% of N-acetylglucosamine. The composition further comprises 4-8% of inulin and 3-6% of resistant dextrin as a matrix filling and slow-release carrier, and the sum of the weight percentages of all the active ingredients and the carrier is 100%. By remodeling intestinal microecology and inhibiting inflammation pathways, the intestinal inflammation state can be remarkably improved, expression of intestinal mucosa tight junction protein is promoted, and an innovative solution is provided for people suffering from chronic bowel diseases and immune imbalance.

The invention belongs to the field of biomedical engineering, and relates to a nutritional composition for delaying muscle attenuation and bone mass reduction based on muscle-bone axis interaction and a preparation method of the nutritional composition. In particular to a nutritional composition which comprises or consists of beta-hydroxy-beta-methylbutyric acid or salt thereof and milk-derived basic protein; wherein the mass ratio of the beta-hydroxy-beta-methylbutyric acid or the salt thereof to the milk-derived basic protein is (120: 1)-(5: 1). According to the nutritional composition disclosed by the invention, through the synergistic effect of the beta-hydroxy-beta-methylbutyric acid or the salt thereof and the milk-derived basic protein, the muscle-bone axis is jointly regulated and controlled, and the comprehensive improvement effect of muscle-bone health which cannot be achieved by a single component is achieved.

The invention relates to the use of beta1,3′-galactosyllactose for improving the gut barrier function. This can in particular be administered to subjects at risk for increased gut barrier permeability, preferably infants and young children.

The invention relates to a nutritional composition comprising non-digestible oligosaccharides for infants and / or young children. The invention further relates to the use of said nutritional composition for improving the brain function, in particular social recognition.

The present invention relates to a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or nutritional compositions comprising the combination. The combination or compositions are for use in treating and / or preventing stress and / or a mood disorder in an infant, young child and / or child. The mixture of HMOs consists or consists essentially of 2′-fucosyllactose (2′FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6′ sialyllactose (6′SL). The present invention also relates to the use of a combination of galacto-oligosaccharides (GOS) and a mixture of human milk oligosaccharides (HMOs), or compositions comprising the combination, for treating and / or preventing stress and / or a mood disorder in an infant, young child and / or child, wherein the mixture of HMOs consists or consists essentially of 2′-fucosyllactose (2′FL) and difucosyllactose (DFL) or of lacto-N-tetraose (LNT) and 6′ sialyllactose (6′SL).

The present invention relates to high density lipoprotein (HDL) or HDL mimetics for use in the prevention and / or treatment of graft-versus-host disease (GvHD) or cytokine release syndrome in a subject.

The present invention provides, among other things, stable formulations comprising an anti-Interleukin 1 Receptor 1 (IL1R1) antibody at a concentration of greater than 80 mg / ml with a pH ranging from 4.4-5.7, wherein the amount of HMW species in the formulation increases less than 2% upon storage at 25° C. for at least 4 weeks.

The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.

Among others, the present disclosure provides methods for extending lifespan or improving healthspan in a mammal, which includes administration to the mammal of a composition containing an effective amount of ergothioneine, or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof.

Certain aspects of the present disclosure provide systems and techniques for rapid detection of repetitive metabolic events in a host based on measured analyte data provided by an analyte monitor worn by the host. An example system is configured to obtain measured glucose data of the host. A subset of the measured glucose data is determined, based on performing a filtering operation on the measured glucose data. A respective range of a likelihood of an occurrence of a metabolic is determined for each value within the subset of the measured glucose data. For at least one value within the subset of the measured glucose data, a state of the metabolic event is determined based in part on at least one of an upper bound or a lower bound of the respective range corresponding to the at least one value within the subset of the measured glucose data.

The present invention provides an antibody pair that binds human mature prolactin, comprising: a monoclonal antibody 1 or an antigen-binding fragment thereof that binds to an N-terminal region of human mature prolactin, and a monoclonal antibody 2 or an antigen-binding fragment thereof that binds to a C-terminal region of human mature prolactin. The present invention also provides use of the antibody pair of the present invention in manufacturing a kit for measuring prolactin in a biological sample. The present invention also provides a monoclonal antibody or an antigen-binding fragment thereof that binds to an N-terminal region of human mature prolactin and a monoclonal antibody or an antigen-binding fragment thereof that binds to a C-terminal region of human mature prolactin, respectively. The present invention also provides a method for measuring prolactin in a biological sample using the antibody pair of the present invention. The present invention also provides a method for producing a monoclonal antibody in the antibody pair of the present invention.